What AI says about GOMEKLI

GOMEKLI (mirdametinib) is the first FDA-approved treatment for adults and children aged 2 and older with symptomatic neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN) that cannot be completely removed by surgery. It is available in capsules or tablets for oral suspension, and the company offers financial support and a digital companion app to help patients manage their treatment.